# Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor

> **NCT07166315** · — · RECRUITING · sponsor: **Adelphi Real World** · enrollment: 700 (estimated)

## Conditions studied

- Axial Spondylarthritis (axSpA)
- Psoriatic Arthritis (PsA)

## Interventions

- **OTHER:** observational study

## Key facts

- **NCT ID:** NCT07166315
- **Lead sponsor:** Adelphi Real World
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-07
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07166315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07166315, "Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07166315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*